This study is looking at a new treatment called ASN51 for people aged 50 to 80 with early Alzheimer's Disease (AD). AD is a condition that affects memory and thinking skills. The study will check if ASN51 is safe and helpful by looking at changes in the brain and body. It will also see how the drug moves through the body, which is called pharmacokinetics (PK). Participants need to have early signs of Alzheimer's and a score of 20 to 28 on a test called the Mini-Mental State Examination, which checks thinking skills. They also need a blood test result that matches Alzheimer's characteristics and a care partner to help give more information. People with other brain conditions or who are taking certain medications can't join.

• The study involves taking multiple doses of ASN51.
• Participants must have a care partner who can provide information about their abilities.
• Some people, like those with other brain diseases, cannot take part.